No single biomarker fully captures the heterogeneity of early BBB dysfunction across neurodegeneration subtypes. A composite scoring algorithm integrating sPDGFRβ (pericyte integrity), soluble thrombomodulin (endothelial damage, sTM), and blood microRNA-320 family members (regulators of pericyte-endothelial crosstalk and tight junction proteins) may establish a robust preclinical 'vascular impairment index.' This panel would be most informative in early/late mild cognitive impairment where intervention potential is highest. The multimodal approach reduces individual biomarker limitations but increases assay complexity and validation burden.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["PDGFRbeta Platelet-Derived Growth Factor"]
B["THBD (Thrombomodulin) Endothelial Marker"]
C["Pericyte Stress Signal"]
D["Circulating Microvesicles"]
E["Blood-Brain Barrier Breakdown"]
F["Neurovascular Uncoupling"]
G["Neuroinflammation Progression"]
H["Cognitive Decline"]
A --> C
B --> C
C --> D
D --> E
E --> F
F --> G
G --> H
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style H fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
8 citations8 with PMIDValidation: 0%4 supporting / 4 opposing
✓For(4)
No supporting evidence
No opposing evidence
(4)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
6
2
MECH 6CLIN 2GENE 0EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
microRNA-320 dysregulation in AD plasma and brain …
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-26 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistic Hypotheses: BBB Permeability Biomarkers for Neurodegeneration
Hypothesis 1: Soluble PDGFRβ as a Peripheral Pericyte Degeneration Marker
Title: Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration
Description: Pericyte degeneration is among the earliest events in Alzheimer's disease (AD) and vascular dementia, preceding amyloid deposition and cognitive symptoms. Damaged pericytes release the ectodomain of platelet-derived growth factor receptor β (sPDGFRβ) into the bloodstream, making it a peripheral indicator o
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Critical Evaluation: BBB Permeability Biomarkers for Neurodegeneration
I will systematically evaluate each hypothesis for mechanistic plausibility, specificity, technical feasibility, and potential confounds. Where applicable, I will identify issues that span multiple hypotheses.
Hypothesis 1: Soluble PDGFRβ (Original: 0.82)
Specific Weaknesses
Non-CNS sources of sPDGFRβ: PDGFRβ is expressed on pericytes, vascular smooth muscle cells (VSMCs), cardiac fibroblasts, hepatic stellate cells, and renal mesangial cells. Systemic inflammatory conditions (atherosclerosis, pul
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Biomarker Utility: HIGH — sPDGFRβ functions as a pharmacodynamic/response biomarker rather than a direct therapeutic target. The underlying PDGFRβ signaling axis, however, represents a legitimate therapeutic target.
Therapeutic Approaches: | Strategy | Agent Class | De
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses": [{"title": "Circulating Soluble PDGFRβ Reflects Pericyte Loss and Precedes Cognitive Decline in Neurodegeneration", "description": "Soluble PDGFRβ (sPDGFRβ) is released into the bloodstream upon pericyte damage, serving as a peripheral indicator of blood-brain barrier (BBB) pericyte coverage loss. Elevated plasma sPDGFRβ correlates with BBB leakage and cognitive decline trajectories. The mechanism involves ADAM10/ADAM17-mediated ectodomain shedding of PDGFRβ from damaged pericytes. This hypothesis has the strongest evidence base with human validation in Alzheimer's dise
IF we measure integrated z-scores of sPDGFRβ, sTM, and miR-320a/b/c in plasma from 200 early MCI participants and 100 cognitively normal controls, THEN the composite panel will discriminate cases from controls with AUC ≥ 0.80, significantly outperforming each biomarker alone (DeLong test p < 0.05), within cross-sectional baseline analysis.
pendingconf: 0.55
Expected outcome: Composite 'vascular impairment index' AUC ≥ 0.80 for early MCI vs controls; each single-marker AUC must be ≤ 0.65
Falsified by: Composite panel AUC < 0.70 OR no significant improvement over best individual biomarker (DeLong p > 0.05)
Method: Prospective observational cohort: ADNI-MCI or comparable longitudinal MCI cohort with plasma sampled at baseline, ELISA for sPDGFRβ/sTM, qRT-PCR for miR-320 family; n=300 total
IF we stratify 150 early MCI participants by high vs low composite panel scores and follow them with annual 3T MRI hippocampal volumetry and fluid cognition testing over 36 months, THEN high-score individuals will show ≥30% faster hippocampal atrophy rate and ≥40% higher incidence of progression to prodromal AD compared to low-score individuals.